This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

C. R. Jeanette Morales-Ducret, MD; Matt van de Rijn, MD; D. P. LeBrun, MD; Bruce R. Smoller, MD

Arch Dermatol. 1995;131(8):909-912.

Abstract
Background and Design
Basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and malignant melanoma (MM) are the three most common malignant neoplasms that arise in the skin. Deregulation of oncogene function not infrequently leads to an increased rate of cellular proliferation. However, the expansion of malignant cells can also occur if programmed cell death is inhibited. The oncogene bcl-2 participates in the regulation of apoptosis (programmed cell death). In view of this, we determined the presence and possible role of bcl-2 in primary cutaneous malignancies. Routine paraffin sections of formalin-fixed BCCs, SCCs, MMs (primary and metastatic), actinic keratoses, and SCCs in situ were labeled with anti-bcl-2 monoclonal antibody using a biotin-avidin-immunoperoxidase procedure.

Results
Twenty-three BCCs were examined and all expressed cytoplasmic bcl-2. Two of 20 SCCs were positive. One of these had patchy, diffuse staining, and the other stained in only small foci. None of eight SCCs in situ and none of eight actinic keratoses expressed bcl-2. Sixteen of 18 MMs expressed bcl-2.

Conclusions
The bcl-2 gene product has been found to inhibit apoptosis. Our preliminary results suggest that the expression of bcl-2 is present quite consistently in BCCs and MMs, but not in SCCs or precursor lesions. The expression (or lack thereof) of bcl-2 may reflect the difference in the regulation of cell turnover between these tumors, or histogenetic differences.

(Arch Dermatol. 1995;131:909-912)

Author Affiliations
From the Departments of Pathology (Drs Morales-Ducret, van de Rijn, LeBrun, and Smoller) and Dermatology (Dr Smoller), Stanford (Calif) University Medical Center.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ultraviolet A-induced Modulation of Bcl-XL by p38 MAPK in Human Keratinocytes: POST-TRANSCRIPTIONAL REGULATION THROUGH THE 3'-UNTRANSLATED REGION
Bachelor and Bowden
J. Biol. Chem. 2004;279:42658-42668.
ABSTRACT | FULL TEXT  

Mechanisms Underlying Imiquimod-Induced Regression of Basal Cell Carcinoma In Vivo
Urosevic et al.
Arch Dermatol 2003;139:1325-1332.
ABSTRACT | FULL TEXT  

Basal Cell Carcinoma With Pulmonary and Lymph Node Metastasis Causing Death
Robinson and Dahiya
Arch Dermatol 2003;139:643-648.
ABSTRACT | FULL TEXT  

Survivin, bcl-2, bax, and bcl-X Gene Expression in Sentinel Lymph Nodes From Melanoma Patients
Gradilone et al.
JCO 2003;21:306-312.
ABSTRACT | FULL TEXT  

A Comparative Review of Melanocytic Neoplasms
Smith et al.
Vet Pathol 2002;39:651-678.
ABSTRACT | FULL TEXT  

bcl-2 vs p53 Protein Expression and Apoptotic Rate in Human Nonmelanoma Skin Cancers
Wikonkal et al.
Arch Dermatol 1997;133:599-602.
ABSTRACT  

Differential Control of Cell Death in the Skin
Norris
Arch Dermatol 1995;131:945-948.
ABSTRACT